1. Severe co-morbidity with life expectancy <3 months according to investigators assessment 2. ASAT/ALAT > 5 times the upper limit of normal 3. Acute co-morbidity within 7 days before inclusion such as myocardial infarction 4. Severe renal impairment, defined as an eGFR <40 mL/min 5. Known intolerance to the available study drugs 6. Pregnancy or breast feeding 7. Any reason why, in the opinion of the investigators, the patient should not participate 8. Subject participates in a potentially confounding drug or device trial during the course of the study 9. Prolonged QTc interval (>470 ms) 10. Cardiac heart failure (Ejection Fraction < 40%, uncompensated) 11. Electrolyte disturbances as hypocalcemia <4.65 mg/dL, hypokalemia <3.4 mmol/L, or hypomagnesia <1.7 mg/dL. However, if the electrolyte disturbances are corrected patient may be included with a delayed start of the test drug 12. Patients already receiving any of the study drugs 13. Patients diagnosed with psoriasis or porphyria 14. Patients receiving any of the following medications: dexametasone, haloperidol, carbamazepine, phenytoin, rifampin, phenobarbital, isoniazid, pyrazinamide, nevirapine, ritonavir, phenytoin or sodium valproate/valproic acid.

1. Severe co-morbidity with life expectancy <3 months according to investigators assessment 2. ASAT/ALAT > 5 times the upper limit of normal 3. Acute co-morbidity within 7 days before inclusion such as myocardial infarction 4. Severe renal impairment, defined as an eGFR <40 mL/min 5. Known intolerance to the available study drugs 6. Pregnancy or breast feeding 7. Any reason why, in the opinion of the investigators, the patient should not participate 8. Subject participates in a potentially confounding drug or device trial during the course of the study 9. Prolonged QTc interval (>470 ms) 10. Cardiac heart failure (Ejection Fraction < 40%, uncompensated) 11. Electrolyte disturbances as hypocalcemia <4.65 mg/dL, hypokalemia <3.4 mmol/L, or hypomagnesia <1.7 mg/dL. However, if the electrolyte disturbances are corrected patient may be included with a delayed start of the test drug 12. Patients already receiving any of the study drugs 13. Patients diagnosed with psoriasis or porphyria 14. Patients receiving any of the following medications: dexametasone, haloperidol, carbamazepine, phenytoin, rifampin, phenobarbital, isoniazid, pyrazinamide, nevirapine, ritonavir, phenytoin or sodium valproate/valproic acid.